Stoke Therapeutics, Inc.STOKEarnings & Financial Report
Nasdaq
STOK Q3 2025 Key Financial Metrics
Revenue
$10.6M
Gross Profit
N/A
Operating Profit
$-43.1M
Net Profit
$-38.3M
Gross Margin
N/A
Operating Margin
-405.3%
Net Margin
-360.7%
YoY Growth
117.2%
EPS
$-0.65
Financial Flow
Stoke Therapeutics, Inc. Q3 2025 Financial Summary
Stoke Therapeutics, Inc. reported revenue of $10.6M for Q3 2025, with a net profit of $-38.3M (-360.7% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $10.6M |
|---|---|
| Net Profit | $-38.3M |
| Gross Margin | N/A |
| Operating Margin | -405.3% |
| Report Period | Q3 2025 |
Stoke Therapeutics, Inc. Annual Revenue by Year
Stoke Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $36.6M).
| Year | Annual Revenue |
|---|---|
| 2024 | $36.6M |
| 2023 | $8.8M |
| 2022 | $12.4M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.8M | $4.2M | $4.8M | $4.9M | $22.6M | $158.6M | $13.8M | $10.6M |
| YoY Growth | -14.3% | -18.2% | 294.7% | 47.9% | 707.4% | 3661.1% | 186.0% | 117.2% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $228.3M | $205.2M | $307.8M | $293.3M | $271.6M | $406.9M | $384.5M | $360.3M |
| Liabilities | $68.8M | $64.8M | $65.0M | $61.2M | $42.5M | $56.8M | $49.6M | $52.2M |
| Equity | $159.6M | $140.3M | $242.7M | $232.1M | $229.0M | $350.1M | $334.9M | $308.1M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-20.6M | $-24.6M | $-17.5M | $-21.6M | $-23.2M | $131.8M | $-25.4M | $-30.4M |